David Lebowitz
Stock Analyst at Citigroup
(1.84)
# 3,195
Out of 4,954 analysts
115
Total ratings
48.28%
Success rate
-0.59%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $18.98 | +5.37% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $195.45 | +48.38% | 14 | Aug 8, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $80 → $77 | $37.84 | +103.49% | 3 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $86.09 | +19.64% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $25.86 | +46.95% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $11.80 | +86.44% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $48.87 | +37.10% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $37.83 | +48.03% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $10.02 | -0.20% | 8 | May 9, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.45 | +3.81% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $64 | $42.43 | +50.84% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $48.71 | -7.62% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $67.02 | +1.46% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $21.19 | +230.34% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $387.38 | -1.39% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $58.29 | +64.69% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $3.36 | +257.14% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $462.01 | -64.50% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $15.76 | +147.46% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $15.73 | +33.55% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.64 | +5,999.40% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.08 | +1,202.33% | 2 | Oct 12, 2021 |
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $18.98
Upside: +5.37%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $195.45
Upside: +48.38%
Cytokinetics
Aug 8, 2025
Maintains: Buy
Price Target: $80 → $77
Current: $37.84
Upside: +103.49%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $86.09
Upside: +19.64%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $25.86
Upside: +46.95%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $11.80
Upside: +86.44%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $48.87
Upside: +37.10%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $37.83
Upside: +48.03%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $10.02
Upside: -0.20%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.45
Upside: +3.81%
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $42.43
Upside: +50.84%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $48.71
Upside: -7.62%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $67.02
Upside: +1.46%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $21.19
Upside: +230.34%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $387.38
Upside: -1.39%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $58.29
Upside: +64.69%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $3.36
Upside: +257.14%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $462.01
Upside: -64.50%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $15.76
Upside: +147.46%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $15.73
Upside: +33.55%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.64
Upside: +5,999.40%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.08
Upside: +1,202.33%